A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer
Open Access
Abstract
Cancer-specific plectin (CSP) is a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, including ovarian cancer (OC). Despite its assessable localization, abundance, and functional significance, the therapeutic efficacy of targeting CSP remains unexplored. Here, we generated and investigated the anticancer effects of a novel CSP-targeting monoclonal antibody, 1H11, in OC models. Its therapeutic efficacy as a monotherapy and in combination with chemotherapy was evaluated in vitro using two OC cell lines and in vivo by a subcutaneous ovarian cancer model. 1H11 demonstrated rapid internalization and high affinity and specificity for both human and murine CSP. Moreover, 1H11 induced significant and selective cytotoxicity (EC50 = 260 nM), G0/G1 arrest, and decreased OC cell migration. Mechanistically, these results are associated with increased ROS levels and reduced activation of the JAK2-STAT3 pathway. In vivo, 1H11 decreased Ki67 expression, induced 65% tumor growth inhibition, and resulted in 30% tumor necrosis. Moreover, 1H11 increased chemosensitivity to cisplatin resulting in 60% greater tumor growth inhibition compared to cisplatin alone. Taken together, CSP-targeting with 1H11 exhibits potent anticancer activity against ovarian cancer and is deserving of future clinical development.Keywords
Funding Information
- ZielBio, Inc. (ZielBio_Peirce-Cottler)
This publication has 65 references indexed in Scilit:
- Variable Metastatic Potentials Correlate with Differential Plectin and Vimentin Expression in Syngeneic Androgen Independent Prostate Cancer CellsPLOS ONE, 2013
- Plectin-1 Targeted AAV Vector for the Molecular Imaging of Pancreatic CancerFrontiers in Oncology, 2013
- Leukotriene B4 Receptor-2 Promotes Invasiveness and Metastasis of Ovarian Cancer Cells through Signal Transducer and Activator of Transcription 3 (STAT3)-dependent Up-regulation of Matrix Metalloproteinase 2Journal of Biological Chemistry, 2012
- Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing TherapyEndocrinology, 2012
- Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cellsOncogene, 2011
- A Functional Proteomic Method for Biomarker DiscoveryPLOS ONE, 2011
- Plectin-1 as a Novel Biomarker for Pancreatic CancerClinical Cancer Research, 2011
- Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomasBritish Journal of Cancer, 2008
- Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal AdenocarcinomaPLOS Medicine, 2008
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences, 2007